{
	"symbol": "AVCN",
	"name": "Avicanna Inc.",
	"price": 0.26,
	"priceChange": -0.005,
	"percentChange": -1.886792,
	"exchangeName": "Toronto Stock Exchange",
	"exShortName": "TSX",
	"exchangeCode": "TSX",
	"marketPlace": null,
	"sector": "Healthcare",
	"industry": "Pharmaceuticals",
	"volume": 6550,
	"openPrice": 0.26,
	"dayHigh": 0.26,
	"dayLow": 0.26,
	"MarketCap": 28488823,
	"MarketCapAllClasses": 28488823,
	"peRatio": "",
	"prevClose": 0.265,
	"dividendFrequency": null,
	"dividendYield": null,
	"dividendAmount": null,
	"dividendCurrency": null,
	"beta": 1.426384,
	"eps": null,
	"exDividendDate": "",
	"longDescription": "Avicanna is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The Company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development that has led to the commercialization of more than twenty products across four main market segments.",
	"fulldescription": "Avicanna is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS Discovery District. The Company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform including advanced R&D and clinical development that has led to the commercialization of more than twenty products across four main market segments.",
	"website": "https://www.avicanna.com",
	"email": "info@avicanna.com",
	"phoneNumber": "+1 647 243-5283",
	"fullAddress": "480 University Avenue,Suite 1502, Toronto, BC, CA",
	"employees": "38",
	"shareOutStanding": 109572395,
	"totalDebtToEquity": 46.07,
	"totalSharesOutStanding": 109572395,
	"sharesESCROW": null,
	"vwap": 0.26,
	"dividendPayDate": null,
	"weeks52high": 0.6,
	"weeks52low": 0.2,
	"alpha": -0.018608,
	"averageVolume10D": 116291,
	"averageVolume20D": 77776,
	"averageVolume30D": 122509,
	"averageVolume50D": 171693,
	"priceToBook": 837.78,
	"priceToCashFlow": -3.2,
	"returnOnEquity": -1063.21,
	"returnOnAssets": -35.55,
	"day21MovingAvg": 0.273095,
	"day50MovingAvg": 0.3148,
	"day200MovingAvg": 0.363075,
	"dividend3Years": "",
	"dividend5Years": "",
	"datatype": "equity",
	"issueType": "CS",
	"close": 0.26,
	"qmdescription": "Pharmaceutical Manufacturers - Cannabis",
	"__typename": "Company"
}